Drug Detail

Drug Name Sorafenib
Trade Name Nexavar
Synonyms BAY 43-9006
Drug Descriptions

Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).

DrugClasses CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RAF Inhibitor (Pan) 17 RET Inhibitor 36 VEGFR2 Inhibitor 34

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Abraxane + Gemcitabine + Sorafenib + Vorinostat
Sorafenib + Hydroxychloroquine
Quinacrine + Sorafenib
Cyclophosphamide + Sorafenib + Topotecan
Bavituximab + Sorafenib
Regorafenib + Sorafenib + MK2206
Clofarabine + Cytarabine + Sorafenib
Pembrolizumab + Sorafenib
Resminostat + Sorafenib
Decitabine + Sorafenib
Sorafenib + Bevacizumab + Oxaliplatin
Sorafenib + Temsirolimus
Bevacizumab + Sorafenib + Temsirolimus
Pictilisib + Sorafenib
Vemurafenib + Sorafenib
Bortezomib + Sorafenib + Decitabine
Cisplatin + Doxorubicin + Sorafenib
Sorafenib + Vinorelbine
Rilutek + Sorafenib
Dalantercept + Sorafenib
Pemetrexed + Sorafenib
CVX-060 + Sorafenib
Cisplatin + Sorafenib + Tamoxifen
Lenalidomide + Sorafenib
Sorafenib + Cisplatin + Paclitaxel
Sorafenib + CC-122
Sorafenib + BEZ235
Sorafenib + Irinotecan
Bevacizumab + Cyclophosphamide + Sorafenib
Erlotinib + Sorafenib
BBI503 + Sorafenib
Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others
Ipafricept + Sorafenib
Nivolumab + Sorafenib
Gemcitabine + Oxaliplatin + Sorafenib
Evofosfamide + Sorafenib
Pimasertib + Sorafenib
Everolimus + Sorafenib
SF1126 + Sorafenib
Carotuximab + Sorafenib
Epirubicin + Ifosfamide + Sorafenib
Busulfan + Sorafenib + Fludarabine
Bevacizumab + Sorafenib
Sorafenib + Cisplatin + Docetaxel
Lenvatinib + Sorafenib
Palbociclib + Sorafenib
Napabucasin + Sorafenib
CVM-1118 + Sorafenib
Fingolimod + Sorafenib
Regorafenib + Sorafenib
Crenolanib + Sorafenib
Selumetinib + Sorafenib
Cetuxmab + Sorafenib
NANT hepatocellular carcinoma vaccine combination
Galunisertib + Sorafenib
Sorafenib + Capecitabine
Selinexor + Sorafenib
Docetaxel + Sorafenib
GW5074 + Sorafenib
Cisplatin + Gemcitabine + Sorafenib
PDR001 + Sorafenib
Sorafenib + Carboplatin + Paclitaxel
Bortezomib + Sorafenib + vorinostat
Sorafenib + Fluorouracil
Panobinostat + Sorafenib
Sorafenib Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).
Trebananib + Sorafenib
Topotecan + Sorafenib
Sorafenib + KD018
Refametinib + Sorafenib
Sorafenib + Vorinostat
Clofarabine + Cytarabine + Dexamethasone + Idarubicin + Sorafenib + Vincristine
Azacitidine + Sorafenib
Doxorubicin + Sorafenib
PX-866 + Sorafenib
GMI-1359 + Sorafenib
Sorafenib + Trametinib
Alvocidib + Sorafenib
Fluorouracil + Quinacrine + Sorafenib
Navitoclax + Sorafenib
Metformin + Sorafenib